治疗前血液参数作为预测局部晚期宫颈癌治疗反应的经济预测指标。

Q2 Pharmacology, Toxicology and Pharmaceutics
F1000Research Pub Date : 2025-04-15 eCollection Date: 2025-01-01 DOI:10.12688/f1000research.160308.2
Abhishek Krishna, Vishnumaya N, Fathima Shada, Pooja Ms, Dilson Lobo, Athiyamaan Ms, Challapalli Srinivas, Sourjya Banerjee, Johan Sunny, Paul Simon
{"title":"治疗前血液参数作为预测局部晚期宫颈癌治疗反应的经济预测指标。","authors":"Abhishek Krishna, Vishnumaya N, Fathima Shada, Pooja Ms, Dilson Lobo, Athiyamaan Ms, Challapalli Srinivas, Sourjya Banerjee, Johan Sunny, Paul Simon","doi":"10.12688/f1000research.160308.2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer poses a significant public health challenge, particularly in low and middle-income countries. Despite advancements in treatment, the disease remains a leading cause of cancer-related deaths among women globally. Chemoradiation utilizing cisplatin has been the cornerstone therapy for locally advanced cervical cancer. Prognostic biomarkers, including hematological parameters, have emerged as valuable tools in guiding treatment decisions and predicting outcomes.</p><p><strong>Methodology: </strong>Data from patients treated between January 2021 and June 2022 were analyzed. Demographic information, histopathology, pre-treatment blood parameters, treatment details, and response assessments were collected. The parameters assessed included hemoglobin levels, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), and eosinophil albumin ratio (EAR). Receiver operating characteristic (ROC) curve analysis was conducted to determine optimal cut-off values for these biomarkers.</p><p><strong>Results: </strong>Of the 140 patients included, the majority had squamous cell carcinoma (92%) and were at stage II or III. Complete response to treatment was observed in 86.4% of patients. Non-responders demonstrated significantly higher levels of hemoglobin, NLR, and EAR, along with lower PNI levels compared to responders. ROC analysis revealed cut-off values for hemoglobin (< 9.5), NLR (< 2.98), PLR (> 289.26), PNI (< 37.67), and EAR (< 49.63) associated with treatment response.</p><p><strong>Conclusion: </strong>The study highlights the potential utility of pre-treatment blood parameters as predictive markers for treatment response in locally advanced cervical cancer. Lower hemoglobin, higher NLR, and EAR, along with reduced PNI, were associated with poorer treatment outcomes. Integration of these biomarkers into clinical practice could aid in treatment planning and improve patient outcomes. Further validation and prospective studies are warranted to establish the role of these biomarkers in guiding personalized treatment strategies for cervical cancer patients.</p>","PeriodicalId":12260,"journal":{"name":"F1000Research","volume":"14 ","pages":"118"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009475/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pre-treatment blood parameters as an economical predictive marker for predicting treatment response in locally advanced cervical cancer.\",\"authors\":\"Abhishek Krishna, Vishnumaya N, Fathima Shada, Pooja Ms, Dilson Lobo, Athiyamaan Ms, Challapalli Srinivas, Sourjya Banerjee, Johan Sunny, Paul Simon\",\"doi\":\"10.12688/f1000research.160308.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cervical cancer poses a significant public health challenge, particularly in low and middle-income countries. Despite advancements in treatment, the disease remains a leading cause of cancer-related deaths among women globally. Chemoradiation utilizing cisplatin has been the cornerstone therapy for locally advanced cervical cancer. Prognostic biomarkers, including hematological parameters, have emerged as valuable tools in guiding treatment decisions and predicting outcomes.</p><p><strong>Methodology: </strong>Data from patients treated between January 2021 and June 2022 were analyzed. Demographic information, histopathology, pre-treatment blood parameters, treatment details, and response assessments were collected. The parameters assessed included hemoglobin levels, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), and eosinophil albumin ratio (EAR). Receiver operating characteristic (ROC) curve analysis was conducted to determine optimal cut-off values for these biomarkers.</p><p><strong>Results: </strong>Of the 140 patients included, the majority had squamous cell carcinoma (92%) and were at stage II or III. Complete response to treatment was observed in 86.4% of patients. Non-responders demonstrated significantly higher levels of hemoglobin, NLR, and EAR, along with lower PNI levels compared to responders. ROC analysis revealed cut-off values for hemoglobin (< 9.5), NLR (< 2.98), PLR (> 289.26), PNI (< 37.67), and EAR (< 49.63) associated with treatment response.</p><p><strong>Conclusion: </strong>The study highlights the potential utility of pre-treatment blood parameters as predictive markers for treatment response in locally advanced cervical cancer. Lower hemoglobin, higher NLR, and EAR, along with reduced PNI, were associated with poorer treatment outcomes. Integration of these biomarkers into clinical practice could aid in treatment planning and improve patient outcomes. Further validation and prospective studies are warranted to establish the role of these biomarkers in guiding personalized treatment strategies for cervical cancer patients.</p>\",\"PeriodicalId\":12260,\"journal\":{\"name\":\"F1000Research\",\"volume\":\"14 \",\"pages\":\"118\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009475/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"F1000Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12688/f1000research.160308.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/f1000research.160308.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

背景:子宫颈癌是一项重大的公共卫生挑战,特别是在低收入和中等收入国家。尽管在治疗方面取得了进步,但该疾病仍然是全球妇女癌症相关死亡的主要原因。顺铂化放疗已成为局部晚期宫颈癌的基础治疗方法。预后生物标志物,包括血液学参数,已经成为指导治疗决策和预测结果的有价值的工具。方法:分析2021年1月至2022年6月期间接受治疗的患者的数据。收集人口统计信息、组织病理学、治疗前血液参数、治疗细节和反应评估。评估的参数包括血红蛋白水平、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、预后营养指数(PNI)和嗜酸性粒细胞白蛋白比值(EAR)。进行受试者工作特征(ROC)曲线分析,以确定这些生物标志物的最佳临界值。结果:在纳入的140例患者中,大多数为鳞状细胞癌(92%),处于II期或III期。86.4%的患者对治疗完全缓解。与应答者相比,无应答者的血红蛋白、NLR和EAR水平明显较高,PNI水平较低。ROC分析显示血红蛋白(< 9.5)、NLR(< 2.98)、PLR (bb0 289.26)、PNI(< 37.67)和EAR(< 49.63)与治疗反应相关。结论:该研究强调了治疗前血液参数作为局部晚期宫颈癌治疗反应的预测指标的潜在效用。较低的血红蛋白、较高的NLR和EAR以及降低的PNI与较差的治疗结果相关。将这些生物标志物整合到临床实践中可以帮助制定治疗计划并改善患者的预后。需要进一步的验证和前瞻性研究来确定这些生物标志物在指导宫颈癌患者个性化治疗策略中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pre-treatment blood parameters as an economical predictive marker for predicting treatment response in locally advanced cervical cancer.

Background: Cervical cancer poses a significant public health challenge, particularly in low and middle-income countries. Despite advancements in treatment, the disease remains a leading cause of cancer-related deaths among women globally. Chemoradiation utilizing cisplatin has been the cornerstone therapy for locally advanced cervical cancer. Prognostic biomarkers, including hematological parameters, have emerged as valuable tools in guiding treatment decisions and predicting outcomes.

Methodology: Data from patients treated between January 2021 and June 2022 were analyzed. Demographic information, histopathology, pre-treatment blood parameters, treatment details, and response assessments were collected. The parameters assessed included hemoglobin levels, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), and eosinophil albumin ratio (EAR). Receiver operating characteristic (ROC) curve analysis was conducted to determine optimal cut-off values for these biomarkers.

Results: Of the 140 patients included, the majority had squamous cell carcinoma (92%) and were at stage II or III. Complete response to treatment was observed in 86.4% of patients. Non-responders demonstrated significantly higher levels of hemoglobin, NLR, and EAR, along with lower PNI levels compared to responders. ROC analysis revealed cut-off values for hemoglobin (< 9.5), NLR (< 2.98), PLR (> 289.26), PNI (< 37.67), and EAR (< 49.63) associated with treatment response.

Conclusion: The study highlights the potential utility of pre-treatment blood parameters as predictive markers for treatment response in locally advanced cervical cancer. Lower hemoglobin, higher NLR, and EAR, along with reduced PNI, were associated with poorer treatment outcomes. Integration of these biomarkers into clinical practice could aid in treatment planning and improve patient outcomes. Further validation and prospective studies are warranted to establish the role of these biomarkers in guiding personalized treatment strategies for cervical cancer patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
F1000Research
F1000Research Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
5.00
自引率
0.00%
发文量
1646
审稿时长
1 weeks
期刊介绍: F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信